Wiseasy Partners with UnionPay International to Boost Digital Banking and QR Payment in Ghana and Nigeria

ACCRA, Ghana, Sept. 10, 2021 /PRNewswire/ — Wiseasy Group, a leading global digital banking and payment builder, jointly announced a collaborative partnership with UnionPay International (UPI) today, to accelerate digital banking and QR payment in Ghana and Nigeria in supporting the global digital transformation trend.

In response to the rapid changing of customer payment needs and the increasingly competitive global financial arena, the two entities collaboratively implement a comprehensive solution, bridging the gaps with their advanced core competencies. This solution provides a unified mobile payment standard and facilitates the management of financial institutions’ mobile payment businesses. Rapid diffusion by Smartphones and QR open new prospects for the development of innovative payment methods and enable customers to carry out banking operations while on the move.

“Wiseasy Group is pleased to be part of this exciting collaboration with UPI to launch a secured, seamless and innovative solution that meets the new expectations of retailers and customers,” stated Mr. Rachid Oulad Akdim, VP Group and President of Wiseasy France.

“We are honoured to partner with Wiseasy Group to further accelerate the brand reach in Ghana and Nigeria”, said Mr. Luping Zhang, General Manager of UnionPay International Africa Branch. “UnionPay continues to offer high quality, cost-effective, innovative payment services through shared growth with our partners in the region”.

Wiseasy Group is a leading global digital banking and payment builder, operating in 114 countries and regions worldwide, covering dozens of industries. The company aims to promote the innovation, development, and application of digital banking solutions and payment technology worldwide by offering smart fintech terminals and rich payment technology services that can reach wider demographics with more convenience.

With over 1.6 billion UnionPay cards issued in 70 countries and regions globally, UnionPay has expanded its acceptance network to 180 countries and regions in recent years. At present, UnionPay cards are widely accepted in Africa across all sectors, effectively meeting the diverse purchasing needs of UnionPay cardholders visiting and living on the continent. UnionPay cards are issued in over 10 African countries, including Kenya, Tanzania, Uganda, Ghana, South Africa, Madagascar and Mauritius. The Nilson Report (Issue 1154) shows that UnionPay ranks first among all card schemes in card issuance and transaction volume worldwide. UnionPay has launched various innovative payment products in Africa in response to the worldwide digital transformation and financial inclusion.

Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19

Independent Data Monitoring Committee Supports Expansion to Adolescents and Pregnant and Nursing Women Based on Safety and Tolerability Data from Phase 2 Lead-In

WALTHAM, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that the independent data monitoring committee (IDMC) for the EVADE Phase 2/3 trial of ADG20 for the prevention of COVID-19 has provided a recommendation to expand Phase 3 trial enrollment to include adolescents and pregnant or nursing women, as well as to decrease the protocol-specified, post injection monitoring time. The IDMC’s assessments are based on their review of unblinded safety and tolerability data from 200 participants enrolled in the Phase 2 lead-in portion of the trial. Adagio remains blinded to the data and plans to implement the IDMC recommendations for the Phase 3 portion of the trial. EVADE is being conducted globally, including in regions where there is a high prevalence of SARS-CoV-2 variants of concern, to evaluate the ability of a single, intramuscular dose of ADG20 to prevent COVID-19 in both pre- and post-exposure settings.

“Given the urgent need for additional treatment and preventative options for COVID-19, particularly in vulnerable populations, we are pleased that an independent assessment of the safety data from the lead-in portion of EVADE supported inclusion of adolescents and pregnant or nursing women in the next phase of the study,” said Lynn Connolly, M.D., Ph.D., chief medical officer of Adagio. “Based on the potent and broad activity of ADG20 in non-clinical studies, as well as its extended half-life and ease of administration, we believe this antibody has the potential to become a preferred prophylactic option for COVID-19, particularly for vulnerable groups such as children and the immunocompromised, for whom there are currently limited or no available options.”

The EVADE trial is a global, multi-center, double-blind, placebo-controlled clinical trial evaluating ADG20 in two independent cohorts. The first cohort (post-exposure prophylaxis) is designed to assess the safety and efficacy of ADG20 compared to placebo for the prevention of COVID-19 after exposure to an individual with laboratory confirmed SARS-CoV-2 infection. The second cohort (pre-exposure prophylaxis) is designed to assess the efficacy and safety of ADG20 compared to placebo in individuals who are at increased risk for SARS-CoV-2 infection due to occupational, housing or recreational situations, and in individuals who are at increased risk of poor vaccine response, including individuals with compromised immune systems or other co-morbidities. The primary efficacy endpoint in both cohorts is the prevention of laboratory confirmed, symptomatic COVID-19. For more information on the EVADE trial, please visit https://clinicaltrials.gov/ct2/show/NCT04859517.

The clinical development program for ADG20 includes two additional trials: the ongoing Phase 1 clinical trial of ADG20 in healthy volunteers and the ongoing STAMP trial evaluating ADG20 as a treatment for high-risk individuals with mild or moderate COVID-19 (see clinicaltrials.gov).

About ADG20
ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses, is being developed for the prevention and treatment of COVID-19, the disease caused by SARS-CoV-2. ADG20 was designed and engineered to possess high potency and broad neutralization against SARS-CoV-2 and additional clade 1 sarbecoviruses, by targeting a highly conserved epitope in the receptor binding domain. ADG20 displays potent neutralizing activity against the original SARS-CoV-2 strain as well as all known variants of concern. ADG20 has the potential to impact viral replication and subsequent disease through multiple mechanisms of action, including direct blocking of viral entry into the host cell (neutralization) and elimination of infected host cells through Fc-mediated innate immune effector activity. ADG20 is formulated at high concentrations, enabling intramuscular administration, and was engineered to have a long half-life, with a goal of providing both rapid and durable protection. Adagio is advancing ADG20 through multiple clinical trials on a global basis.

About Adagio Therapeutics
Adagio is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company’s portfolio of antibodies has been optimized using Adimab’s industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio’s portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com.

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com


Disruptive.Asia constate que les fabricants chinois de puces tirent parti de l’innovation et de l’appui aux politiques pour atteindre la maturité en 14 nm

LONDRES, 10 septembre 2021 /PRNewswire/ — Disruptive.Asia constate que la quête d’autosuffisance de la Chine en matière de fabrication de puces permet non seulement de doper les capacités de fabrication de puces de 14 nm en vue de leur pleine maturité, mais aussi de positionner le pays comme un partenaire mondial clé dans le secteur des chipsets, au moment où la chaîne d’approvisionnement se déplace vers la région Asie-Pacifique.

Selon Cai Yimao, vice-doyen de l’École d’ingénierie électronique et d’informatique de l’Université de Pékin, les entreprises chinoises ont surmonté bon nombre des difficultés techniques inhérentes à la conception de puces de 14 nm, ce qui a permis d’accélérer les capacités de la Chine en matière de puces de 14 nm au cours des deux dernières années. Le secteur chinois des puces en 28 nm devrait atteindre sa pleine maturité cette année et les puces en 14 nm devraient suivre d’ici 2022.

Les fabricants de puces en Chine bénéficient d’un appui aux politiques et d’investissements importants. M. Cai estime que la promulgation de politiques pertinentes a clairement montré que la Chine continue de soutenir l’industrie des circuits intégrés en tant qu’industrie phare. La Chine accorde une grande importance au développement de l’industrie des circuits intégrés et renforce continuellement l’appui aux politiques et les investissements.

Actuellement, la chaîne d’approvisionnement se déplace vers la Chine et l’Asie du Sud-Est. On pense que cela stimulera également la R&D nationale en matière de technologies avancées et favorisera un développement rapide des entreprises locales en Chine à mesure qu’elles accumuleront des compétences technologiques et une expérience de gestion. En outre, l’achèvement progressif de la construction de nouvelles usines de production de plaquettes en Chine continentale apporte un nouveau soutien à l’industrie des puces en termes de réduction des coûts, de renforcement des capacités de production et de commodité géographique. Le nombre et la proportion des lignes de production de circuits intégrés en Chine ne cessent d’augmenter. Plus de 20 300 mm de lignes de production ont été mis en service, et plusieurs sont en cours de construction.

Disruptive.Asia convient que la Chine a déjà maîtrisé la technologie de la production de masse des puces de 14 nm. Comme l’a mentionné M. Cai, les puces chinoises en 14 nm seront produites en masse l’année prochaine, avec un meilleur équilibre entre performances, consommation d’énergie et coût comme jamais auparavant.

À propos de Disruptive.Asia

Disruptive.Asia  assure la couverture de l’état actuel de la révolution numérique dans les secteurs des télécoms, des fintechs et de l’Internet dans la région Asie-Pacifique – son origine, ce qui la fait avancer, l’impact qu’elle a sur chaque industrie, comment les acteurs clés y répondent et ce que nous réserve l’avenir.

Denmark Lifts All COVID Curbs After Successful Vaccination Drive

COPENHAGEN – Denmark Friday dropped proof-of-vaccination — or vaccine passports — requirements at nightclubs, the last of the European nation’s COVID-19 restrictions, after a successful vaccination program led to almost 87% of all adults being fully vaccinated.

The European Center for Disease Control says as of Friday, nearly 90% of adults in Denmark have at least one dose and nearly 70% of its entire population.

Officials have been gradually lifting restrictions as vaccination levels increased, lifting mask requirements on public transportation August 14, and reopening nightclubs, lifting limits on public gatherings, and use of the vaccine passports at restaurants, sporting events and other venues September 1.

Denmark’s health minister, Magnus Heunicke, said last month the epidemic appears to be under control but warned the government will act as needed if the situation deteriorates.

Face masks or shields are still mandatory at airports and people are advised to wear one when at the doctor’s, test centers or hospitals.

Distancing is still recommended, and strict entry restrictions still apply for non-citizens at the borders.

The outbreak is still considered “an ordinary dangerous illness” in Denmark.

Source: Voice of America

White House COVID-19 Response Team Defends Biden Plan

The White House COVID-19 response team Friday used its regular briefing to support and defend the new round of vaccination mandates announced a day earlier by U.S. President Joe Biden.

Part of Biden’s plan calls for the U.S. Department of Labor to implement an emergency rule requiring all employers with 100 or more employees to ensure their workers are fully vaccinated or show a negative test at least once a week. The plan would cover more than 80 million workers. Non-compliance could bring fines of as much as nearly $14,000 per violation.

The plan drew criticism from Republican lawmakers and state governors. But during the team’s virtual briefing, White House Coronavirus Response Coordinator Jeff Zients called the president’s plan an aggressive, comprehensive way to get more people vaccinated, which is the surest path out of the pandemic.

He reiterated getting vaccinated is a public health issue, not a political one.

Zients said statistics show vaccine mandates work. He said when the president announced his mandate for federal employees to be fully vaccinated in July, hundreds of businesses, colleges and universities, health care systems, and state and local governments followed his lead.

Zients pointed out that since large companies like Tyson Foods and United Airlines announced similar requirements, vaccination numbers rose substantially. Tyson, for example, saw vaccination numbers go from 45% to 72%, with nearly two months to go before its November deadline, Zients said.

Centers for Disease Control Director Rochelle Walensky said this remains a pandemic of the unvaccinated, with more than 90% of people hospitalized with COVID-19 unvaccinated, more than 10 times the number of vaccinated patients.

The team said the pace of U.S. vaccinations has picked up, with 14 million people receiving their first shots in August, four million more than in July. The CDC reports more than 73% of U.S. residents, age 12 and older, have now received at least one vaccination and 62.5% are fully vaccinated.

Source: Voice of America

NASA to Discuss First Rock Sample Collected on Mars

The U.S. space agency on Friday will brief the media on the initial analysis of the first sample of a Martian rock collected by its Perseverance rover earlier this week.

NASA confirmed the rover had collected the rock, releasing a picture of the sample inside a collection tube. The rover made a first attempt to collect a sample in early August, but the rock crumbled during the drilling and coring process.

The rover moved to a different location earlier this month where the team selected a rock that held up better.

Over the past week, scientists have been using Perseverance’s instruments to analyze the sample and they are expected to reveal what they have discovered at Friday’s briefing.

Former NASA research director Scott Hubbard — now a professor at Stanford University — told the Associated Press the collection “is a huge step forward in what the science community has wanted for more than 50 years, which is to bring samples back from the Red Planet.”

He said the sample appears to be one that could be dated, a main goal of collecting such rocks, along with looking for evidence of past or present biological life. A key objective for Perseverance’s mission on Mars is astrobiology, including the search for signs of ancient microbial life.

The plan is for subsequent NASA missions, in cooperation with the European Space Agency, to send spacecraft to Mars to collect Perseverance’s sealed samples from the surface and bring them to Earth for in-depth analysis.

Perseverance landed in Jezero Crater February 18, and the rover team kicked off the science phase of its mission June 1.

Source: Voice of America

UNHCR Angola Population of Concern Snapshot – August 2021

Overview

UNHCR has been in Angola for 43 years since the signing of the ‘Accord de Siege’ in February 1977. During this time, UNHCR has played an important role in the history of Angola such as leading the repatriation of Angolans who fled the long civil war. With reestablishment of peace in 2002, the Government of Angola asked for UNHCR support to facilitate repatriation of Angolan refugees. After voluntarily repatriation took place, from 2003 until 2015, more than 523,000 Angolan refugees returned, more than half coming from the Democratic Republic of Congo (DRC). From 2015 to 2016, UNHCR Angola operation focused on urban refugees and asylum seekers. In 2017, influx of refugees fleeing Kasai region in DRC forced the operation to scale up. The Field Office Dundo was established and, eventually, the Lovua Settlement in Lundo Norte. Currently, there are more than 56,000 refugees and asylum seekers in Angola spread over provinces such as Luanda and Lunda Norte. These refugees represent a multitude of countries such as the DRC, Rwanda, Mauritania and others. They are located in several provinces across Angola, including Luanda and Lunda Norte. UNHCR is a key observer of the National Council for Refugees (CNR) and works with several partners on the ground to ensure that refugees and person at risk of statelessness are protected and have access to livelihood and durable solutions.

Refugees from DRC include regular caseload and Kasai caseload. Kasai caseload comprised of 9,695 individuals out of which 6,801 are residing in Lovua refugee settlement while 2,894 individuals are in out of camp settings. They are the refugees originating from Kasai region of DRC who came to Lunda Norte province in Angola as a result of conflict in 2017 and were given Prima Facie refugee status. The regular caseload consists of the remaining population ( 46,802) excluding the 2017 Kasai caseload and comprises of refugees and asylum-seekers who came to Angola as far as 35 years ago. The regular caseload includes urban refugees from different nationalities including Congolese, majority of them settled in Luanda but also in the other 12 provinces.

Source: UN High Commissioner for Refugees

ANGOLA CHAIRS COMMITTEE SESSION OF OACPS AMBASSADORS

Luanda – The President of the Committee of Ambassadors of the Organisation of African, Caribbean and Pacific States (OACPS) Mário de Azevedo Constantino chaired Thursday a special session of the body he leads.

The organisation states in its note that the session held in Brussels, Belgium, received the President of Guinea Bissau Umaro Sissoco Emalo, who visited that country.

Delivering his welcome speech, Mário de Azevedo Constantino highlighted, among other aspects, the implementation of the new partnership in the economy and the initiatives for the recovery in post-covid-19 pandemic era.

According to ambassador, the president Umaro Sissoco Embalo visit coincides with an important period in the life of the organisation, which is working on operation of dispositions of the revised Georgetown Agreement and, at the same time, to improve the inter regional cooperation.

He said that following the signing of the new Partnership Agreement of ACP and the European Union (EU), the organisation is working on creation of structures and necessary mechanisms for its effectiveness.

According to the Angolan diplomat, the new Agreement opens room for cooperation with EU and demands the countries of the organisation to put into practice the principles of subsidiary, complementary and personality which add value in the Intra ACP relations.

He also said a new Agreement to reinforce the continent and regional agendas, like that of 2063 in Africa, will contribute to the deepening and enlargement of the regional integration in Caribbean and Pacific zone.

Angola started on 01 August a six-month presidency at the helm of Committee of Ambassadors and the Council of Ministers of ACP.

Source: Angola Press News Agency